CDC Endorses Newly-Approved GSK Shingles Vaccine

The Centers for Disease Control and Prevention’s vaccination policy advisory committee endorsed Shingrix, GlaxoSmithKline’s newly-approved shingles drug.

The advisory committee favored the drug over the older vaccine, Merck’s Zostavax. In an 8-7 vote, it recommended the shot for individuals 50 and older, whereas earlier recommendations had applied to patients 60 and older.

Final approval of the committee’s endorsement will be up to the CDC.